Custom mRNA vaccine targets biliary cancer recurrence
NCT ID NCT07368803
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This trial tests a personalized mRNA vaccine called iNeo-Vac-R01 in 20 adults with biliary cancer who have had surgery to remove their tumors. The vaccine is designed to train the immune system to attack cancer cells based on each patient's unique tumor markers. The main goal is to check safety, but researchers will also track how long patients stay cancer-free and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital
RECRUITINGHangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.